Drug Information

Drug General Information
Drug ID
D0X0IU
Former ID
DIB007839
Drug Name
LMB-2
Synonyms
LMB-2a; AntiTac(Fv)-PE38; Immunotoxin (cancer), National Cancer Institute
Indication Chronic lymphocytic leukaemia [ICD10:C91] Phase 2 [525749]
Company
National Cancer Institute
Target and Pathway
Target(s) Interleukin-2 receptor alpha chain Target Info Modulator [525749]
KEGG Pathway Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
Jak-STAT signaling pathway
Hematopoietic cell lineage
Measles
HTLV-I infection
NetPath Pathway IL5 Signaling Pathway
TCR Signaling Pathway
IL2 Signaling Pathway
TNFalpha Signaling Pathway
Leptin Signaling Pathway
PANTHER Pathway Interleukin signaling pathway
Pathway Interaction Database IL12-mediated signaling events
Calcineurin-regulated NFAT-dependent transcription in lymphocytes
Arf6 trafficking events
SHP2 signaling
IL2-mediated signaling events
IL2 signaling events mediated by PI3K
IL2 signaling events mediated by STAT5
Calcium signaling in the CD4+ TCR pathway
Downstream signaling in na&#xef
IL12 signaling mediated by STAT4
Reactome GPVI-mediated activation cascade
G beta:gamma signalling through PI3Kgamma
Interleukin-2 signaling
RAF/MAP kinase cascade
Interleukin receptor SHC signaling
WikiPathways IL-2 Signaling Pathway
Inflammatory Response Pathway
Interleukin-2 signaling
Allograft Rejection
TSLP Signaling Pathway
IL-7 Signaling Pathway
Interleukin-3, 5 and GM-CSF signaling
References
Ref 525749Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.
Ref 525749Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol. 2000 Apr;18(8):1622-36.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.